Venus Remedies has bagged the coveted UBM India Pharma Award for its flagship product, Elores, in the Excellence in Product Development category in Mumbai recently. The award ceremony recognised select, path-breaking initiatives undertaken by the pharmaceutical industry in key areas of quality, product design, cost management, packaging, corporate social responsibility and research & development. Among the jury members for the awards were Dr Ajit Dangi, President and Chief Executive Officer, Danssen Consulting, Devinder Pal, President, Catalyst Pharma Consult, and Kaushik Desai, Director (India region), Drug Information Association.
Asserting that this prestigious award is a recognition of Venus Remedies’ competitive edge in research-based products and its innovative approach, Dr Manu Chaudhary, Director, Research, Venus Medicine Research Centre, said, “It is a matter of great pride for the entire VMRC team to have received this award for Elores. This is the second award for Elores in the first year of its launch, and we are expecting this product to generate revenue of around $100 million by 2017-18.”
Launched in January this year, Elores is a novel antibiotic adjuvant entity that effectively counters serious hospital-acquired infections caused by multidrug-resistant extended-spectrum beta-lactamase (ESBL) and metallo-beta-lactamase (MBL)-producing gram negative bacteria.
EP News Bureau – Mumbai
- Advertisement -
